A phase 3 trial shows retatrutide, a triple-action weekly injection for type 2 diabetes, reduced blood sugar levels by more than twice that of placebo and produced over four times greater weight loss in 930 patients over 40 weeks. The drug mimics three gut hormones to control appetite, blood sugar, and metabolism, with side effects mostly mild and gastrointestinal in nature.
Topicle Beta
2 comments
A phase 3 trial shows retatrutide, a triple-action weekly injection for type 2 diabetes, reduced blood sugar levels by more than twice that of placebo and produced over four times greater weight loss in 930 patients over 40 weeks. The drug mimics three gut hormones to control appetite, blood sugar, and metabolism, with side effects mostly mild and gastrointestinal in nature.
This is very interesting news. Just a note to the OP we do have a health sub.